Korea reinstates market approval of sibutramine

The Korean Food and Drug Administration said on July 20 it has concluded that the benefit/risk assessment of sibutramine is favorable and will its continued sale here after convening the Central Pharmaceutical Affairs Review Committee meeting on July 19 to discuss the drug's benefit/risk profile and determine if additional regulatory actions should be taken.

However, the drug agency cautione...